# Wrap Technologies, Inc.: financial statements, quarterly

WRAP · Nasdaq · CIK 1702924 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wrap.md) · [Financials](/companies/wrap/financials.md) · [Filings](/companies/wrap/filings.md) · [Insiders](/companies/wrap/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wrap/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.6](/filings/0001437749-24-035368.md) | [0.6 d](/filings/0001641172-25-001416.md) | [1.5](/filings/0001641172-25-011065.md) | [1.6](/filings/0001641172-25-024162.md) | [0.6](/filings/0001140361-25-041816.md) | [0.9 d](/filings/0001140361-26-011401.md) | [0.8](/filings/0001140361-26-021091.md) | [1.0](/filings/0001140361-26-032276.md) | [1.5](/filings/0001140361-25-041816.md) | [1.4 d](/filings/0001140361-26-011401.md) | [1.1](/filings/0001140361-26-021091.md) | [2.1](/filings/0001140361-26-032276.md) |
| Cost of revenue | $m | [1.5](/filings/0001437749-24-035368.md) | [0.9 d](/filings/0001641172-25-001416.md) | [0.6](/filings/0001641172-25-011065.md) | [0.6](/filings/0001641172-25-024162.md) | [0.4](/filings/0001140361-25-041816.md) | [0.5 d](/filings/0001140361-26-011401.md) | [0.2](/filings/0001140361-26-021091.md) | [0.5](/filings/0001140361-26-032276.md) | [0.6](/filings/0001140361-25-041816.md) | [0.7 d](/filings/0001140361-26-011401.md) | [0.4](/filings/0001140361-26-021091.md) | [0.5](/filings/0001140361-26-032276.md) |
| Gross profit | $m | [2.2](/filings/0001437749-24-035368.md) | [(0.3) d](/filings/0001641172-25-001416.md) | [0.8](/filings/0001641172-25-011065.md) | [1.0](/filings/0001641172-25-024162.md) | [0.2](/filings/0001140361-25-041816.md) | [0.4 d](/filings/0001140361-26-011401.md) | [0.6](/filings/0001140361-26-021091.md) | [0.5](/filings/0001140361-26-032276.md) | [0.9](/filings/0001140361-25-041816.md) | [0.7 d](/filings/0001140361-26-011401.md) | [0.7](/filings/0001140361-26-021091.md) | [1.5](/filings/0001140361-26-032276.md) |
| Research and development | $m | [0.6](/filings/0001437749-24-035368.md) | [0.6 d](/filings/0001641172-25-001416.md) | [0.8](/filings/0001641172-25-011065.md) | [0.7](/filings/0001641172-25-024162.md) | [0.5](/filings/0001140361-25-041816.md) | [0.4 d](/filings/0001140361-26-011401.md) | [0.4](/filings/0001140361-26-021091.md) | [0.2](/filings/0001140361-26-032276.md) | [0.2](/filings/0001140361-25-041816.md) | [(0.6) d](/filings/0001140361-26-011401.md) | [0.1](/filings/0001140361-26-021091.md) | [0.2](/filings/0001140361-26-032276.md) |
| Selling, general and administrative | $m | [4.3](/filings/0001437749-24-035368.md) | [5.8 d](/filings/0001641172-25-001416.md) | [4.2](/filings/0001641172-25-011065.md) | [3.5](/filings/0001641172-25-024162.md) | [3.3](/filings/0001140361-25-041816.md) | [4.7 d](/filings/0001140361-26-011401.md) | [4.1](/filings/0001140361-26-021091.md) | [3.2](/filings/0001140361-26-032276.md) | [3.5](/filings/0001140361-25-041816.md) | [5.2 d](/filings/0001140361-26-011401.md) | [5.4](/filings/0001140361-26-021091.md) | [3.6](/filings/0001140361-26-032276.md) |
| Operating income | $m | [(2.8)](/filings/0001437749-24-035368.md) | [(6.6) d](/filings/0001641172-25-001416.md) | [(4.1)](/filings/0001641172-25-011065.md) | [(3.2)](/filings/0001641172-25-024162.md) | [(3.6)](/filings/0001140361-25-041816.md) | [(4.6) d](/filings/0001140361-26-011401.md) | [(3.9)](/filings/0001140361-26-021091.md) | [(2.9)](/filings/0001140361-26-032276.md) | [(2.8)](/filings/0001140361-25-041816.md) | [(3.9) d](/filings/0001140361-26-011401.md) | [(4.8)](/filings/0001140361-26-021091.md) | [(2.3)](/filings/0001140361-26-032276.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(2.8)](/filings/0001437749-24-035368.md) | [(18.4) d](/filings/0001641172-25-001416.md) | [0.1](/filings/0001641172-25-011065.md) | [(0.4)](/filings/0001641172-25-024162.md) | [2.0](/filings/0001140361-25-041816.md) | [(7.6) d](/filings/0001140361-26-011401.md) | [0.1](/filings/0001140361-26-032276.md) | [(3.7)](/filings/0001140361-26-032276.md) | [(2.8)](/filings/0001140361-25-041816.md) | [(3.9) d](/filings/0001140361-26-011401.md) | [(4.5)](/filings/0001140361-26-032276.md) | [(2.3)](/filings/0001140361-26-032276.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | [(0.02)](/filings/0001641172-25-024162.md) | [0.04](/filings/0001140361-25-041816.md) | not reported | [0.00](/filings/0001140361-26-021091.md) | [(0.07)](/filings/0001140361-26-032276.md) | [(0.06)](/filings/0001140361-25-041816.md) | not reported | [(0.09)](/filings/0001140361-26-021091.md) | [(0.04)](/filings/0001140361-26-032276.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001437749-24-035368.md) | not reported | [0.00](/filings/0001437749-24-029935.md) | [(0.02)](/filings/0001641172-25-024162.md) | [0.04](/filings/0001140361-25-041816.md) | not reported | [0.00](/filings/0001140361-26-021091.md) | [(0.07)](/filings/0001140361-26-032276.md) | [(0.06)](/filings/0001140361-25-041816.md) | not reported | [(0.09)](/filings/0001140361-26-021091.md) | [(0.04)](/filings/0001140361-26-032276.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.9](/filings/0001437749-23-031987.md) | [4.0](/filings/0001641172-25-001416.md) | [3.2](/filings/0001437749-24-029935.md) | [2.1](/filings/0001437749-24-031161.md) | [4.9](/filings/0001437749-24-035368.md) | [3.6](/filings/0001140361-26-011401.md) | [6.2](/filings/0001641172-25-011065.md) | [4.2](/filings/0001641172-25-024162.md) | [6.0](/filings/0001140361-25-041816.md) | [3.5](/filings/0001140361-26-032276.md) | [7.3](/filings/0001140361-26-021091.md) | [4.8](/filings/0001140361-26-032276.md) |
| Current assets | $m | [25.8](/filings/0001437749-23-031987.md) | [21.2](/filings/0001641172-25-001416.md) | [17.7](/filings/0001437749-24-029935.md) | [15.0](/filings/0001437749-24-031161.md) | [12.2](/filings/0001437749-24-035368.md) | [10.5](/filings/0001140361-26-011401.md) | [13.5](/filings/0001641172-25-011065.md) | [11.3](/filings/0001641172-25-024162.md) | [13.6](/filings/0001140361-25-041816.md) | [11.4](/filings/0001140361-26-032276.md) | [14.5](/filings/0001140361-26-021091.md) | [13.2](/filings/0001140361-26-032276.md) |
| Total assets | $m | [31.7](/filings/0001437749-23-031987.md) | [28.5](/filings/0001641172-25-001416.md) | [24.8](/filings/0001437749-24-029935.md) | [21.8](/filings/0001437749-24-031161.md) | [18.8](/filings/0001437749-24-035368.md) | [15.1](/filings/0001140361-26-011401.md) | [18.0](/filings/0001641172-25-011065.md) | [15.6](/filings/0001641172-25-024162.md) | [18.2](/filings/0001140361-25-041816.md) | [15.4](/filings/0001140361-26-032276.md) | [16.7](/filings/0001140361-26-021091.md) | [15.3](/filings/0001140361-26-032276.md) |
| Current liabilities | $m | [10.8](/filings/0001437749-23-031987.md) | [23.5](/filings/0001641172-25-001416.md) | [18.5](/filings/0001437749-24-029935.md) | [16.2](/filings/0001437749-24-031161.md) | [10.7](/filings/0001437749-24-035368.md) | [13.2](/filings/0001140361-26-011401.md) | [13.8](/filings/0001641172-25-011065.md) | [2.0](/filings/0001641172-25-024162.md) | [1.9](/filings/0001140361-25-041816.md) | [1.8](/filings/0001140361-26-032276.md) | [1.9](/filings/0001140361-26-021091.md) | [1.6](/filings/0001140361-26-032276.md) |
| Total liabilities | $m | [11.1](/filings/0001437749-23-031987.md) | [25.3](/filings/0001641172-25-001416.md) | [20.3](/filings/0001437749-24-029935.md) | [17.9](/filings/0001437749-24-031161.md) | [12.4](/filings/0001437749-24-035368.md) | [14.9](/filings/0001140361-26-011401.md) | [15.4](/filings/0001641172-25-011065.md) | [3.9](/filings/0001641172-25-024162.md) | [4.1](/filings/0001140361-25-041816.md) | [3.9](/filings/0001140361-26-032276.md) | [2.3](/filings/0001140361-26-021091.md) | [2.0](/filings/0001140361-26-032276.md) |
| Shareholders' equity | $m | [20.6](/filings/0001437749-24-035368.md) | [3.2](/filings/0001140361-26-011401.md) | [4.5](/filings/0001641172-25-024162.md) | [3.8](/filings/0001140361-25-041816.md) | [6.4](/filings/0001140361-25-041816.md) | [0.3](/filings/0001140361-26-032276.md) | [2.6](/filings/0001140361-26-032276.md) | [11.8](/filings/0001140361-26-032276.md) | [14.1](/filings/0001140361-25-041816.md) | [11.5](/filings/0001140361-26-032276.md) | [14.4](/filings/0001140361-26-032276.md) | [13.3](/filings/0001140361-26-032276.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.1) d](/filings/0001437749-24-035368.md) | [(3.8) d](/filings/0001641172-25-001416.md) | [(3.7)](/filings/0001641172-25-011065.md) | [(3.5) d](/filings/0001641172-25-024162.md) | [0.3 d](/filings/0001140361-25-041816.md) | [(1.2) d](/filings/0001140361-26-011401.md) | [(3.1)](/filings/0001140361-26-021091.md) | [(1.9) d](/filings/0001140361-26-032276.md) | [(2.6) d](/filings/0001140361-25-041816.md) | [(2.7) d](/filings/0001140361-26-011401.md) | [(1.2)](/filings/0001140361-26-021091.md) | [(2.4) d](/filings/0001140361-26-032276.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001437749-24-035368.md) | [0.1 d](/filings/0001641172-25-001416.md) | [0.0](/filings/0001641172-25-011065.md) | [(0.0) d](/filings/0001641172-25-024162.md) | [0.0 d](/filings/0001140361-25-041816.md) | [(0.0) d](/filings/0001140361-26-011401.md) | [0.0](/filings/0001140361-26-021091.md) | [0.0 d](/filings/0001140361-26-032276.md) | [0.1 d](/filings/0001140361-25-041816.md) | [0.0 d](/filings/0001140361-26-011401.md) | [0.0](/filings/0001140361-26-021091.md) | [0.0 d](/filings/0001140361-26-032276.md) |
| Dividends paid | $m | [0.0 d](/filings/0001437749-24-035368.md) | [0.1 d](/filings/0001641172-25-001416.md) | [0.1](/filings/0001641172-25-011065.md) | [0.1 d](/filings/0001641172-25-024162.md) | [0.0 d](/filings/0001140361-25-041816.md) | [0.0 d](/filings/0001140361-26-011401.md) | not reported | not reported | not reported | [0.0 d](/filings/0001140361-26-011401.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [44.2](/filings/0001641172-25-011065.md) | [45.3](/filings/0001641172-25-024162.md) | [45.9](/filings/0001140361-25-041816.md) | [48.4](/filings/0001140361-26-021091.md) | [50.6](/filings/0001140361-26-032276.md) | [51.1](/filings/0001140361-25-041816.md) | [54.0](/filings/0001140361-26-021091.md) | [55.7](/filings/0001140361-26-032276.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 56,003,638 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001140361-26-032276.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.